DaVita (NYSE:DVA) Stock Crosses Above 200-Day Moving Average – Should You Sell?

DaVita Inc. (NYSE:DVA)’s stock price passed above its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $179.73 and traded as high as $183.50. DaVita shares last traded at $183.1590, with a volume of 573,314 shares traded.

Wall Street Analyst Weigh In

DVA has been the topic of a number of recent research reports. UBS Group upped their price objective on DaVita from $270.00 to $287.00 and gave the stock a “buy” rating in a research report on Monday, November 2nd. Oppenheimer set a $220.00 target price on DaVita in a report on Friday, August 7th. TD Cowen boosted their target price on DaVita from $220.00 to $228.00 and gave the stock a “buy” rating in a research note on Monday, November 2nd. Weiss Ratings raised DaVita from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Friday, October 9th. Finally, Deutsche Bank reaffirmed a “buy” rating and issued a $265.00 price target on shares of DaVita in a research report on Wednesday, August 5th. Four analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. According to data from MarketBeat.com, DaVita presently has an average rating of “Moderate Buy” and an average price target of $235.86.

DaVita Trading Up 0.4%

The firm’s fifty day simple moving average is $182.71 and its 200 day simple moving average is $180.06. The company has a market cap of $11.00 billion, a price-to-earnings ratio of 12.87, a PEG ratio of 0.46 and a beta of 0.87.

DaVita (NYSE:DVA) last announced its quarterly earnings data on Thursday, October 29th. The company reported $3.82 earnings per share for the quarter, beating analysts’ consensus estimates of $3.57 by $0.25. The business had revenue of $3.58 billion for the quarter, compared to analyst estimates of $3.52 billion. DaVita had a net margin of 6.49% and a negative return on equity of 225.93%. The company’s revenue was up 4.6% on a year-over-year basis. During the same period last year, the business earned $2.51 EPS. As a group, sell-side analysts expect that DaVita Inc. will post 14.66 EPS for the current year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the business. Te Ahumairangi Investment Management Ltd raised its holdings in DaVita by 28.6% during the third quarter. Te Ahumairangi Investment Management Ltd now owns 54,798 shares of the company’s stock worth $9,585,000 after purchasing an additional 12,186 shares in the last quarter. AlphaGrep UK Ltd purchased a new position in shares of DaVita in the 3rd quarter valued at $433,000. Allianz SE acquired a new stake in DaVita during the 3rd quarter worth $128,000. Advisors Asset Management Inc. acquired a new stake in DaVita during the 3rd quarter worth $433,000. Finally, Private Advisor Group LLC acquired a new stake in DaVita during the 3rd quarter worth $214,000. Hedge funds and other institutional investors own 90.12% of the company’s stock.

DaVita Company Profile

DaVita Inc. is a healthcare provider focused on kidney care. Its core business is operating outpatient dialysis centers that provide treatment and related services to people with chronic kidney failure. The company also offers home dialysis programs, provides dialysis services to patients in hospitals, and supports kidney care through services such as care coordination and education. DaVita primarily serves patients in the United States and also operates in international markets. Founded in 1994 as Total Renal Care, the company adopted the name DaVita in 2000.